![\"\"](\"https:\/\/i0.wp.com\/www.shqiperia.com\/blog\/wp-content\/uploads\/2020\/10\/gettyimages-182497159-079c84cfc6ad5499f13ffff24e61df5245b0714b-s800-c85-905x395-1.jpg?resize=501%2C232&ssl=1\")
<\/p>\n<\/p>\n
Remdesivir, ila\u00e7i i fort\u00eb q\u00eb u p\u00ebrdor nga Trump e Berlusconi dhe po sh\u00ebron t\u00eb s\u00ebmur\u00ebt r\u00ebnd\u00eb me Covid-19. – A do nis\u00eb p\u00ebrdorimi edhe n\u00eb Shqip\u00ebri?<\/strong><\/p>\n 10 tetor \u00a02020<\/p>\n N\u00eb nj\u00eb raport t\u00eb botuar n\u00eb 8 tetor n\u00eb New England Journal of Medicine, studiuesit konfirmuan p\u00ebrfitimet e Remdesivir p\u00ebr trajtimin e t\u00eb shtruarve n\u00eb spital me COVID-19.<\/p>\n Ky ila\u00e7 antiviral, ka autorizimin e p\u00ebrdorimit emergjent (EUA) nga Administrata e Ushqimit dhe Barnave t\u00eb SHBA-s\u00eb (FDA) p\u00ebr trajtimin e kujtdo t\u00eb shtruar p\u00ebr shkak t\u00eb k\u00ebsaj s\u00ebmundjeje. Ky autorizim do t\u00eb thot\u00eb se mjek\u00ebt mund ta k\u00ebshillojn\u00eb medikamentin intravenoz (IV) p\u00ebr njer\u00ebzit q\u00eb jan\u00eb t\u00eb infektuar me SARS-CoV-2 dhe jan\u00eb n\u00eb gjendje t\u00eb r\u00ebnduar.<\/p>\n Teksa ila\u00e7i ishte autorizuar fillimisht vet\u00ebm p\u00ebr ata q\u00eb kishin nevoj\u00eb p\u00ebr oksigjen shtes\u00eb ose ventilator p\u00ebr t\u00eb marr\u00eb frym\u00eb, nj\u00eb EUA e zgjeruar nga FDA n\u00eb fund t\u00eb gushtit pasqyron besimin n\u00eb rritje mes mjek\u00ebve q\u00eb trajtimi i njer\u00ebzve, t\u00eb cil\u00ebt nuk jan\u00eb dhe aq t\u00eb s\u00ebmur\u00eb mund t\u00eb siguroj\u00eb edhe m\u00eb shum\u00eb p\u00ebrfitime \u2013 p\u00ebr k\u00ebt\u00eb arsye, tani n\u00eb mjekim p\u00ebrfshihen dhe persona me shenja t\u00eb infeksionit t\u00eb frym\u00ebmarrjes por q\u00eb nuk kan\u00eb ende nevoj\u00eb p\u00ebr oksigjen shtes\u00eb apo ndihm\u00ebn e nj\u00eb respiratori.<\/p>\n Remdesivir vepron duke penguar aft\u00ebsin\u00eb e virusit p\u00ebr t\u00eb b\u00ebr\u00eb m\u00eb shum\u00eb kopje t\u00eb vetvetes, dhe n\u00eb testime, ka ndihmuar si pacient\u00ebt me faz\u00eb t\u00eb hershme COVID-19 ashtu edhe ata me simptoma m\u00eb t\u00eb avansuara. N\u00eb raportin e fundit, studiuesit e udh\u00ebhequr nga nj\u00eb ekip i Institutit Komb\u00ebtar t\u00eb Alergjis\u00eb dhe S\u00ebmundjeve Infektive, p\u00ebrcjellin t\u00eb dh\u00ebnat p\u00ebrfundimtare t\u00eb studimit q\u00eb nis\u00ebn fillimisht n\u00eb muajin maj.<\/p>\n N\u00eb analiz\u00ebn finale, e cila p\u00ebrfshiu 1,062 persona t\u00eb p\u00ebrcaktuar rast\u00ebsisht p\u00ebr t\u00eb marr\u00eb Remdesivir IV ose nj\u00eb placebo p\u00ebr deri n\u00eb 10 dit\u00eb teksa ishin n\u00eb spital, studiuesit ofrojn\u00eb informacione m\u00eb t\u00eb holl\u00ebsishme se si ila\u00e7i ndikoi tek metrika, duke p\u00ebrfshir\u00eb k\u00ebtu edhe sa koh\u00eb u duhej dh\u00ebn\u00eb njer\u00ebzve oksigjen plot\u00ebsues ose vendosja n\u00eb respirator. T\u00eb gjith\u00eb pjes\u00ebmarr\u00ebsit kishin shenja t\u00eb infeksionit t\u00eb frym\u00ebmarrjes, kryesisht pneumoni, dhe 85% konsiderohej se ishin t\u00eb s\u00ebmur\u00eb r\u00ebnd\u00eb q\u00eb do t\u00eb thoshte se ata kishin t\u00eb pakt\u00ebn nj\u00eb nga tre simptomat: nivelet e oksigjenit n\u00eb gjak ishin n\u00ebn 94%; k\u00ebrkonin oksigjen shtes\u00eb ose u duhej nj\u00eb respirator p\u00ebr t\u00eb marr\u00eb frym\u00eb.<\/p>\n Midis t\u00eb gjith\u00eb pjes\u00ebmarr\u00ebsve \u2013 si t\u00eb s\u00ebmur\u00ebt m\u00eb r\u00ebnd\u00eb me COVID-19 t\u00eb r\u00ebnd\u00eb, ashtu edhe ata me simptoma m\u00eb t\u00eb lehta \u2013 personat t\u00eb cil\u00ebve iu administrua Remdesivir ishin n\u00eb gjendje t\u00eb dilnin nga spitali mesatarisht pes\u00eb dit\u00eb m\u00eb shpejt sesa ata q\u00eb merrnin trajtimin me placebo. \u201cK\u00ebto t\u00eb dh\u00ebna p\u00ebrforcojn\u00eb vler\u00ebn e Remdesivirit te pacient\u00ebt e shtruar n\u00eb spital\u201d, thot\u00eb doctor John Beigel, drejtor i asociuar i k\u00ebrkimit klinik n\u00eb nj\u00ebsi\u00ebn e mikrobiologjis\u00eb dhe s\u00ebmundjeve infektive n\u00eb NIAID.<\/p>\n Nd\u00ebrsa studimi paraprak ofroi t\u00eb dh\u00ebna p\u00ebr vdekshm\u00ebrin\u00eb pas 15 dit\u00ebsh, studimi i plot\u00eb ndoqi pjes\u00ebmarr\u00ebsit n\u00eb studim p\u00ebr 28 dit\u00eb dhe zbuloi se mes atyre q\u00eb mor\u00ebn Remdesivir, vdiq\u00ebn 11% krahasuar me 15% n\u00eb mesin e grupit placebo. Nd\u00ebrsa ky nuk \u00ebsht\u00eb nj\u00eb ndryshim i r\u00ebnd\u00ebsish\u00ebm statistikisht (studimi nuk ishte aq i madh sa t\u00eb p\u00ebrfshinte nj\u00ebshkall\u00eb t\u00eb gjerr\u00eb njer\u00ebzish), ai konsiderohet s\u00ebrish \u201cnj\u00eb p\u00ebrmir\u00ebsim i r\u00ebnd\u00ebsish\u00ebm\u201d, sipas Beigel.<\/p>\n Ai v\u00ebren se nivelet e vdekshm\u00ebris\u00eb, t\u00eb marra s\u00eb bashku me matjet e tjera, duke p\u00ebrfshir\u00eb faktin q\u00eb p\u00ebrdoruesit e Remdesivir kaluan m\u00eb pak koh\u00eb n\u00eb oksigjen dhe m\u00eb pak dit\u00eb n\u00eb spital, mb\u00ebshtesin p\u00ebrfitimet e p\u00ebrgjithshme t\u00eb ila\u00e7it.<\/p>\n P\u00ebrve\u00e7 k\u00ebsaj, v\u00eb n\u00eb dukje Beigel, ila\u00e7i dukej se ndihmonte jo vet\u00ebm ata njer\u00ebz q\u00eb kishin simptoma p\u00ebr m\u00eb shum\u00eb se 10 dit\u00eb, por edhe atyre t\u00eb cil\u00ebve u ishin shfaqur simptoma p\u00ebr m\u00eb pak se 10 dit\u00eb. Kjo \u00ebsht\u00eb p\u00ebrpjekja m\u00eb e r\u00ebnd\u00ebsishme e sutdiuesve p\u00ebr t\u00eb par\u00eb m\u00eb konkretisht sesi ndikon ila\u00e7i tek pacient\u00ebt q\u00eb jan\u00eb n\u00eb fazat e hershme t\u00eb COVID-19. K\u00ebto teste po eksplorojn\u00eb n\u00ebse Remdesivir mund t\u00eb zvog\u00ebloj\u00eb p\u00ebrparimin e COVID-19 edhe tek individ\u00ebt q\u00eb nuk jan\u00eb shtruar n\u00eb spital dhe potencialisht i mban ata t\u00eb mos s\u00ebmuren aq sa t\u00eb ken\u00eb nevoj\u00eb p\u00ebr shtrim n\u00eb spital.<\/p>\n \u201cT\u00eb dish se si funksionojn\u00eb infeksionet virale t\u00eb frym\u00ebmarrjes dhe si funksionon ky ila\u00e7, t\u00eb ndihmon shum\u00eb\u201d, thot\u00eb Beigel. \u201cNuk ka asnj\u00eb arsye p\u00ebr t\u00eb menduar se nuk do t\u00eb funksiononte p\u00ebr pacient\u00ebt; por duhen b\u00ebr\u00eb studime\u201d, shton ai. Sfida e vetme tani p\u00ebr tani \u00ebsht\u00eb q\u00eb Remdesivir \u00ebsht\u00eb nj\u00eb ila\u00e7 IV, dhe logjistika e menaxhimit t\u00eb injeksioneve IV p\u00ebr njer\u00ebzit q\u00eb nuk jan\u00eb t\u00eb shtruar n\u00eb spital mund t\u00eb kufizoj\u00eb p\u00ebrdorimin e tij. Por prodhuesi i ila\u00e7it, Gilead, thot\u00eb se po teston edhe nj\u00eb version t\u00eb ilacit q\u00eb mund t\u00eb merret me t\u00eb thithur, cka do t\u00eb ishte m\u00eb e leht\u00eb p\u00ebr pacient\u00ebt.<\/p>\n Po n\u00eb Shqip\u00ebri?<\/p>\n